---
title: 'Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated
  Apoptotic Responses'
date: '2024-06-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38941598/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240629181447&v=2.18.0.post9+e462414
source: Blood
description: 'T-prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm associated
  with marked chemotherapy resistance and continued poor clinical outcomes. Current
  treatments, i.e. the CD52-antibody alemtuzumab, offer transient responses, with
  relapses being almost inevitable without consolidating allogeneic transplantation.
  Recent more detailed concepts of T-PLL''s pathobiology fostered the identification
  of actionable vulnerabilities: (i) altered epigenetics, (ii) defective DNA damage
  responses, ...'
disable_comments: true
---
T-prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm associated with marked chemotherapy resistance and continued poor clinical outcomes. Current treatments, i.e. the CD52-antibody alemtuzumab, offer transient responses, with relapses being almost inevitable without consolidating allogeneic transplantation. Recent more detailed concepts of T-PLL's pathobiology fostered the identification of actionable vulnerabilities: (i) altered epigenetics, (ii) defective DNA damage responses, ...